Analysts/Institutional Investor Meet/Con. Call Updates

Ref: ISLL:CH:2026 Date: 20th August, 2026 The President The Vice President, Corporate Relationship Department Listing Compliance Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (E), Mumbai 400 051 BSE Scrip Code: 532305 NSE Symbol: INDSWFTLAB Sub: Transcript of Earnings Conference Call on Un- Audited Financial Results for the Quarter ended June, 30 2026 Respected Sir/Ma’am, Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), and other applicable provisions, as amended from time to time, kindly find enclosed herewith the transcript of the Conference Call held on Monday, August 17, 2026, with Analysts/Investors to discuss the Un-audited Financial Results of the Company for the quarter ended June 30, 2026 (Q1 FY27). You are requested to kindly take the same on record. With Regards, For IND-SWIFT LABORATORIES LTD. PARDEEP VERMA VP-CORPORATE AFFAIRS & COMPANY SECRETARY Encl: As Above Ind-Swift Laboratories Ltd. Q1 FY27 Earnings Call Transcript Management: Mr. Pardeep Verma – VP-Corporate Affairs & Company Secretary Mr. Gagan Aggarwal – Chief Financial Officer Ind-Swift Laboratories Ltd. Q1 FY27 Earnings Call Transcript Moderator: Ladies and gentlemen, good afternoon and welcome to the Ind-Swift Laboratories Q1 FY27 conference call, hosted by ConfideLeap Partners. As a reminder, all the participants' line will be in listen mode only, and there will be an opportunity for you to ask the questions after the presentation concludes. Please note that this conference is being recorded. Before we begin, I would like to point out that this conference may contain forward-looking statements about the company, which are based upon the beliefs, opinions, and expectations of the company as of the date of the call. These statements do not guarantee the future performance of the company, and they may involve risks and uncertainties that are difficult to predict. We represent the Investor Relations for Ind-Swift Laboratories Limited. The company is represented by Mr. Gagan Aggarwal, who is the Chief Financial Officer, Mr. Pardeep Verma, the VP of Corporate Affairs and CS, and Ms. Shalika Malhotra, DGM Finance of Ind-Swift Laboratories. I would now like to hand over the call to Mr. Pardeep Verma for his opening remarks. Thank you and over to you, Pardeep sir. Pardeep Verma: Thank you, Ameya. Good afternoon, everyone, and a very warm welcome to the Q1 FY27 earnings call of Ind-Swift Laboratories Limited. On behalf of the Company, I thank you all for joining us today to discuss our operational and financial performance for the quarter ended 30th June, 2026. Let me take you through the business and financial updates for the quarter, following which we will open the floor for the question-and-answer session. Q1 FY27 has been an excellent start to the year for Ind-Swift Laboratories, and I am pleased to share that the Company has delivered a strong quarter of performance, both operationally and financially, as we continue to build on our transformation from an API player into a focused, pure-play Finished Dosage Formulation, or FDF, manufacturer. Let me first take you through the key operational developments during the quarter. Our CDMO partnerships with Viatris, Manx in the UK, and Arrotex in Australia have now been commercialised during the quarter. These are expected to contribute an incremental revenue of ₹200 to ₹220 crore in FY27, and represent a key milestone in scaling our contract manufacturing business with global generic majors. We commercialised two new products during the quarter: Ibuprofen Sachet for the European market and Macrogol Sachet for the UK and Australian markets. Our total dossiers filed increased to 2,100+, up from 1,915+ previously. Global product registrations increased to 850-plus, compared with 750-plus previously, expanding the Company's presence across international markets. The planned upgrade of our Samba manufacturing facility to EU-GMP and PIC/S standards is currently underway and progressing as planned. This is expected to enhance our export capabilities, support product filings across regulated markets, and strengthen our long-term growth visibility. Let me also touch upon product-wise revenue mix, which continues to reflect a well-diversified portfolio across our key export molecules. Atorvastatin remained our largest contributor, with revenue growing to ₹85.50 crore in FY26 from ₹47.96 crore in FY25 and continues to be a molecule with a large and growing addressable market globally. Ezetimibe + Atorvastatin saw the sharpest growth in the portfolio with year-on-year growth of 246.97%, more than tripling to ₹80.78 crore in FY26 from ₹23.28 crore in FY25. Fexofenadine remained a steady contributor at ₹74.32 crore in FY26, broadly in line with ₹79.67 crore in FY25. Metformin, Quetiapine and Famciclovir each registered excellent growth during the year, with Quetiapine nearly doubling to ₹19.75 crore and Famciclovir more than doubling to ₹18.64 crore in FY26. This product mix underscores the depth of our export portfolio, and going forward, our upcoming launches, including Clarithromycin dry suspension with expected launch in this year and Esomeprazole with Viatris and Arrotex with expected launch in FY28, are expected to further strengthen this revenue base over the coming years. Turning to our segment-wise sales breakup for the quarter, we continue to see a meaningful shift toward our export business, which remains the primary growth engine for the company. Our brands within our export segment contributed 57.20% of quarterly sales in Q1 FY27, up sharply from 48% in Q1 FY26, reflecting deeper own-brand penetration, establishing trust and growing grip in the export markets. Increase in our own-brand revenue contribution year-on-year has been a key driver for expansion in our margin profile. Contract manufacturing within exports stood at 26.64% of quarterly sales in Q1 FY27 compared to 29% in Q1 FY26, as the mix continues to shift in favour of high-margin own-brands. Branded generics within the domestic market contributed 6.41% of the sales in Q1 FY27 compared to 10% in Q1 FY26. The ethical division stood at 6.14% of the sales in Q1 FY27 compared to 7% in Q1 FY26. Contract manufacturing within domestic contributed 3.61% of the sales in Q1 FY27 compared to 6% in Q1 FY26. Overall, our export business, comprising own-brands and contract manufacturing together, has scaled up meaningfully as a proportion of total sales while our domestic segments, namely branded generic, ethical division and contract manufacturing, continue to provide a stable cash generation base for the company. This growing tilt towards exports and particularly towards own-brands is consistent with our stated strategy of deepening our regulatory market presence and improving overall profitability. Turning now to our financial performance for the quarter, operating income grew 21.16% year-on-year to ₹186.08 crore from ₹153.58 crore in Q1 FY26. Operating EBITDA improved 2.85x year-on-year to ₹33.32 crore from ₹8.66 crore in the corresponding quarter last year. Operating EBITDA margin expanded sharply by 1258 bps year-on-year to 17.91% from 5.33% in Q1 FY26. PAT excluding exceptional item stood at ₹24.68 crore, a 2.04x year-on-year jump from ₹8.12 crore. PAT margin improved by 827bps year-on-year to 13.26% from 4.99% in the corresponding quarter of the previous year. This consistent improvement across our revenue, EBITDA margin, PAT margin and export mix gives us confidence in the operating momentum we are building, and we remain focused on sustaining this trajectory through the rest of FY27. With this, I now hand over the floor for the question-and- answer session. Thank you. Moderator: Thank you, Pardeep sir. P [Showing first 8,000 characters — download PDF for full document]